These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21376008)

  • 1. Characterization of side reactions during the annealing of small interfering RNAs.
    Seiffert S; Debelak H; Hadwiger P; Jahn-Hofmann K; Roehl I; Vornlocher HP; Noll B
    Anal Biochem; 2011 Jul; 414(1):47-57. PubMed ID: 21376008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of small interfering RNA by non-denaturing ion-pair reversed-phase liquid chromatography.
    Noll B; Seiffert S; Vornlocher HP; Roehl I
    J Chromatogr A; 2011 Aug; 1218(33):5609-17. PubMed ID: 21737080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversed-phase ion-pair liquid chromatography analysis and purification of small interfering RNA.
    McCarthy SM; Gilar M; Gebler J
    Anal Biochem; 2009 Jul; 390(2):181-8. PubMed ID: 19345196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining ion pairing agents for enhanced analysis of oligonucleotide therapeutics by reversed phase-ion pairing ultra performance liquid chromatography (UPLC).
    Levin DS; Shepperd BT; Gruenloh CJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1587-95. PubMed ID: 21514903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural characterization and biological evaluation of small interfering RNAs containing cyclohexenyl nucleosides.
    Nauwelaerts K; Fisher M; Froeyen M; Lescrinier E; Aerschot AV; Xu D; DeLong R; Kang H; Juliano RL; Herdewijn P
    J Am Chem Soc; 2007 Aug; 129(30):9340-8. PubMed ID: 17616127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo sequence determination of modified oligonucleotides.
    Farand J; Gosselin F
    Anal Chem; 2009 May; 81(10):3723-30. PubMed ID: 19438262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of strong anion-exchange (SAX) magnetic particles for the extraction of therapeutic siRNA and their analysis by liquid chromatography/mass spectrometry.
    Ye G; Beverly M
    Rapid Commun Mass Spectrom; 2011 Nov; 25(21):3207-15. PubMed ID: 22006382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification of small interfering RNA using nondenaturing anion-exchange chromatography.
    Noll B; Seiffert S; Hertel F; Debelak H; Hadwiger P; Vornlocher HP; Roehl I
    Nucleic Acid Ther; 2011 Dec; 21(6):383-93. PubMed ID: 22017541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligonucleotide charge reversal: 2'-O-lysylaminohexyl modified oligonucleotides.
    Winkler J; Noe CR
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):939-42. PubMed ID: 18058513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity.
    Ferrari N; Bergeron D; Tedeschi AL; Mangos MM; Paquet L; Renzi PM; Damha MJ
    Ann N Y Acad Sci; 2006 Oct; 1082():91-102. PubMed ID: 17145930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo.
    Laursen MB; Pakula MM; Gao S; Fluiter K; Mook OR; Baas F; Langklaer N; Wengel SL; Wengel J; Kjems J; Bramsen JB
    Mol Biosyst; 2010 May; 6(5):862-70. PubMed ID: 20567772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of active small interfering RNAs.
    Peek AS; Behlke MA
    Curr Opin Mol Ther; 2007 Apr; 9(2):110-8. PubMed ID: 17458163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications.
    Dande P; Prakash TP; Sioufi N; Gaus H; Jarres R; Berdeja A; Swayze EE; Griffey RH; Bhat B
    J Med Chem; 2006 Mar; 49(5):1624-34. PubMed ID: 16509579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Separation of oligonucleotide phosphorothioate diastereoisomers by pellicular anion-exchange chromatography.
    Thayer JR; Wu Y; Hansen E; Angelino MD; Rao S
    J Chromatogr A; 2011 Feb; 1218(6):802-8. PubMed ID: 21216401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultra-performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) and UPLC/MS(E) analysis of RNA oligonucleotides.
    Ivleva VB; Yu YQ; Gilar M
    Rapid Commun Mass Spectrom; 2010 Sep; 24(17):2631-40. PubMed ID: 20740540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradation product characterization of therapeutic oligonucleotides using liquid chromatography mass spectrometry.
    Elzahar NM; Magdy N; El-Kosasy AM; Bartlett MG
    Anal Bioanal Chem; 2018 May; 410(14):3375-3384. PubMed ID: 29654340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LNA incorporated siRNAs exhibit lower off-target effects compared to 2'-OMethoxy in cell phenotypic assays and microarray analysis.
    Puri N; Wang X; Varma R; Burnett C; Beauchamp L; Batten DM; Young M; Sule V; Latham K; Sendera T; Echeverri C; Sachse C; Magdaleno S
    Nucleic Acids Symp Ser (Oxf); 2008; (52):25-6. PubMed ID: 18776235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separation of small interfering RNA stereoisomers using reversed-phase ion-pairing chromatography.
    Li L; Leone T; Foley JP; Welch CJ
    J Chromatogr A; 2017 Jun; 1500():84-88. PubMed ID: 28449879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.